NCT00020397View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2000

Study Completion Date

July 31, 2005

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

NY-ESO-1 peptide vaccine

BIOLOGICAL

aldesleukin

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00020397 - Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma | Biotech Hunter | Biotech Hunter